Literature DB >> 9255206

Prospective multicenter study of sulfonylurea ingestion in children.

H A Spiller1, D Villalobos, E P Krenzelok, B D Anderson, S E Gorman, S R Rose, J Fenn, D L Anderson, S J Muir, G C Rodgers.   

Abstract

OBJECTIVE: Sixty-eight percent of pediatric sulfonylurea ingestions reported to poison centers do not result in laboratory or behavioral effects. Consequently, if all exposed children are admitted overnight or for 24 hours for these exposures, it will result in 600 to 700 hospital admissions per year of children who will remain free of symptoms. We prospectively studied exposures reported to 10 regional poison centers to determine if it were possible to differentiate those patients who would have symptoms from those who would remain symptom free.
METHODS: We analyzed all sulfonylurea exposures in children < or = 12 years old reported to the participating poison centers. Hypoglycemia was defined as blood glucose (BG) concentration < 60 mg/dl.
RESULTS: Hypoglycemia developed in 56 (30%) of 185 exposed patients. Fifty-four of the 56 (96%) hypoglycemic patients had development of hypoglycemia within 8 hours of ingestion. Eighty-seven of the patients were initially managed with oral supplementation only; in 13 cases, treatment advanced to intravenous administration of glucose or glucagon with the onset of hypoglycemia. There was no statistical difference in medical outcome between patients monitored during oral supplementation versus during intravenous infusion of dextrose. Ingestions analyzed by time of day did not predict risk of hypoglycemia. Sufficient data were available for 103 (58%) of the 177 patients who ingested glyburide or glipizide to calculate a toxic dose/weight ratio. Of these 103 patients, 31 of 36 patients who ingested < or = 0.3 mg/kg remained symptom free, whereas 31 of 67 who ingested more than 0.3 mg/kg had BG concentrations < 60 mg/dl (p < 0.005, 95% confidence interval 0.05 to 0.58; sensitivity 86%, specificity 46%).
CONCLUSION: A lack of onset of hypoglycemia (BG > 60 mg/dl) in the first 8 hours after ingestion is predictive of a benign outcome in accidental pediatric sulfonylurea ingestion. Clinical observation of children for onset of hypoglycemia during oral feeding alone appears safe. Some children with symptoms of hypoglycemia need to receive intravenous dextrose therapy. Time of day of ingestion is not predictive of risk of hypoglycemia. Finally, at this time it appears inappropriate to use a milligram per kilogram body weight dose as a guide for management decisions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255206     DOI: 10.1016/s0022-3476(97)70138-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Deliberate sulphonylurea poisoning mimicking hyperinsulinaemia of infancy.

Authors:  L Owen; M Ellis; J Shield
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

2.  Unwitnessed sulphonylurea poisoning in a healthy toddler.

Authors:  Pei Ying Loo; Fabian Yap
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

3.  Case files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion.

Authors:  Diane P Calello; Andrea Kelly; Kevin C Osterhoudt
Journal:  J Med Toxicol       Date:  2006-03

Review 4.  Octreotide's role in the management of sulfonylurea-induced hypoglycemia.

Authors:  Patrick P Dougherty; Wendy Klein-Schwartz
Journal:  J Med Toxicol       Date:  2010-06

5.  Sulfonylurea Poisoning in a Healthy Toddler.

Authors:  Suresh Kumar; Abhijit Choudhary; Mahammad Ali; Vipul Gupta; Jayashree Muralidharan; Sunit C Singhi
Journal:  Indian J Pediatr       Date:  2016-10-31       Impact factor: 1.967

Review 6.  Management of antidiabetic medications in overdose.

Authors:  H A Spiller
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

7.  Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide.

Authors:  Paul I Pelavin; Erika Abramson; Steven Pon; Maria G Vogiatzi
Journal:  J Pediatr Endocrinol Metab       Date:  2009-02       Impact factor: 1.634

Review 8.  Treatment of sulfonylurea and insulin overdose.

Authors:  Wendy Klein-Schwartz; Gina L Stassinos; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2016-01-06       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.